Sex Differences in the Treatment of People with Parkinson’s Disease with a Device-Aided Therapy: A Prospective Real-World Study
Authors:
- Diego Santos GarcíaDGDiego Santos García
- Ángela Solleiro VidalÁVÁngela Solleiro Vidal
- Marta Blázquez EstradaMEMarta Blázquez Estrada
- Pablo MirPMPablo Mir
- Nuria López ArizteguiNANuria López Ariztegui
- Déborah Alonso ModinoDMDéborah Alonso Modino
- Inés LegardaILInés Legarda
- Alejandro PeralAPAlejandro Peral
- Rocío García-RamosRGRocío García-Ramos
- Iria CaboICIria Cabo
- Pilar Sánchez AlonsoPAPilar Sánchez Alonso
- Jorge Hernández-VaraJHJorge Hernández-Vara
Open Access
- 27 April 2026
- journal article
- research article
- Published by MDPI AG in Medical Sciences
- Vol. 14 (2) , 217
Abstract
Background and Objective: Sex differences in the treatment of people with Parkinson’s disease (PwP) with a device-aided therapy (DAT) have been poorly investigated. Our aim was to analyze sex differences in the management and response to a DAT in PwP in daily clinical practice (DCP). Patients and Methods: Data collected in the DATs-PD GETM Spanish Registry until 30 October 2025 were used. This is a descriptive, observational, prospective, and multicenter clinical registry with progressive inclusion of PwP treated with a DAT in DCP conditions in more than 40 centers from Spain. Sex differences in the DAT received and changes in quality of life (QoL), motor symptoms (MS), non-motor symptoms (NMS), and autonomy for activities of daily living (AADL) after 6 months of treatment were analyzed. Results: A total of 618 PD patients (66.9 ± 9.5 years old; 57.6% men) were treated with a DAT. A significant difference was observed in the DAT type according to sex (p = 0.006), with 73.1% of PwP who were treated with deep brain stimulation being men. At the time of DAT indication, women were older, received a higher levodopa equivalent daily dose, and had a worse health-related QoL and AADL. OFF time decreased, whereas MS and NMS burden and health-related QoL improved at 6 months follow-up in both groups (men and women). AADL improved only in men during the OFF state. Conclusion: Sex differences were detected in the use of DATs in PwP. Improvement in OFF time, MS, NMS, and QoL was detected in both groups.Keywords
Funding Information
- Fundación Degen
- Sociedad Española de Neurologia
- Grupo de Estudio de Trastornos del Movimiento
This publication has 52 references indexed in Scilit:
- Continuous Subcutaneous Versus Intestinal Levodopa Infusion for Parkinson's Disease: A Real‐World, Monocentric, Observational Study and Critical ReviewMovement Disorders Clinical Practice, 2026
- Ethnic and Gender Disparities in Access to Deep Brain Stimulation Surgery for Parkinson's DiseaseMovement Disorders Clinical Practice, 2025
- Profile of People With Parkinson's Disease Treated With a Device‐Aided Therapy in Spain. A Comparative Multicenter Observational StudyMovement Disorders Clinical Practice, 2025
- Levodopa–Entacapone–Carbidopa Intrajejunal Infusion in Advanced Parkinson's Disease – Interim Analysis of the ELEGANCE StudyMovement Disorders Clinical Practice, 2025
- Concomitant Medication Usage with Levodopa‐Carbidopa Intestinal Gel: Results from the COSMOS StudyMovement Disorders, 2021
- Differences in the Presentation and Progression of Parkinson's Disease by SexMovement Disorders, 2020
- MDS clinical diagnostic criteria for Parkinson's diseaseMovement Disorders, 2015
- Levodopa‐carbidopa intestinal gel in advanced Parkinson's disease: Final 12‐month, open‐label resultsMovement Disorders, 2014
- EuroInf: AMulticenter Comparative Observational Study of Apomorphine and Levodopa Infusion in Parkinson's DiseaseMovement Disorders, 2014
- Gender-related differences in the burden of non-motor symptoms in Parkinson’s diseaseJournal of Neurology, 2012